Neuronetics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $STIM in the last 30 days.
See all $STIM insider activity →BTIG maintained a Buy rating on Neuronetics with a $6 price target, suggesting 117.4% upside from the last close. The company reported 17% revenue growth and introduced a new go-to-market strategy, aiming to expand its customer base and improve operational efficiency.
Neuronetics (STIM) is integrating its NeuroStar TMS technology with AdvancedMD's platform, aiming to streamline clinical and billing coordination for TMS treatments. The integration, targeting Q4 release, connects TrakStar with AdvancedMD's EHR and revenue-cycle system, benefiting over 65,000 practitioners. Neuronetics plans further EHR/EMR integrations. Collaborative Solutions in Psychiatry piloted the program, reporting efficiency gains.
Neuronetics Inc (STIM) shares rose 3.5% after B.Riley initiated coverage with a Buy rating and $5.00 price target, citing potential earnings growth from the Greenbrook acquisition and a shift in interventional psychiatry. The analyst sees 70% upside from current levels, noting STIM trades at a lower multiple than peers.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning STIM (Neuronetics, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent STIM coverage spans earnings, technology and financial news.
BTIG maintained a Buy rating on Neuronetics with a $6 price target, suggesting 117.4% upside from the last close. The company reported 17% revenue growth and introduced a new go-to-market strategy, aiming to expand its customer base and improve operational efficiency.
Potential boost to NeuroStar adoption and revenue through streamlined workflow for mental health practices.
Analyst upgrade and price target suggest upside potential.
Potential operational efficiencies for NeuroStar providers may boost adoption and revenue over time.
Guidance narrowing and margin expansion expectations are the key near-term drivers for STIM positioning, alongside cash burn and ATM proceeds.
AlphAI scores every news story that mentions STIM with an AI model for sentiment and relevance, and aggregates insider trades from Neuronetics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG maintained a Buy rating on Neuronetics with a $6 price target, suggesting 117.4% upside from the last close. The company reported 17% revenue growth and introduced a new go-to-market strategy, aiming to expand its customer base and improve operational efficiency.
1 min readNeuronetics (STIM) is integrating its NeuroStar TMS technology with AdvancedMD's platform, aiming to streamline clinical and billing coordination for TMS treatments. The integration, targeting Q4 release, connects TrakStar with AdvancedMD's EHR and revenue-cycle system, benefiting over 65,000 practitioners. Neuronetics plans further EHR/EMR integrations. Collaborative Solutions in Psychiatry piloted the program, reporting efficiency gains.
2 min readNeuronetics Inc (STIM) shares rose 3.5% after B.Riley initiated coverage with a Buy rating and $5.00 price target, citing potential earnings growth from the Greenbrook acquisition and a shift in interventional psychiatry. The analyst sees 70% upside from current levels, noting STIM trades at a lower multiple than peers.
2 min readNeuronetics, Inc. integrated its TrakStar platform with AdvancedMD, Inc.'s EHR system. This is the first TMS system to integrate with an EHR/EMR. The collaboration aims to streamline clinical, operational, and billing workflows. The integration will be available to NeuroStar providers using AdvancedMD in Q4. Early adopter CSIP reported reduced duplicate work and improved operations.
2 min readNeuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.
6 min readNeuronetics, Inc. (STIM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 11, 2026, in connection with Mr. Naor’s appointment (as described below), Francis X. Brown III’s appointment
2 min readChernett Jorey purchased 14,000 shares of Neuronetics, Inc. (STIM) at $3.16 on 2026-08-14.
1 min readNeuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.
5 min readNeuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.
6 min readNeuronetics (STIM) reported Q2 2026 revenue of $41.6 million, up 9.1% year over year, with Greenbrook revenue rising 16.8% to $26.9 million. Gross margin increased to 51.1%. Adjusted EBITDA turned positive at $0.3 million. Net loss narrowed to $3.4 million. Full-year 2026 revenue guidance is $160-$164 million and gross margin 48%-50%.
4 min read
